HC2 Holdings, a diversified holding company, announced today that BeneVir Biopharm, Inc., a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”). BeneVir is a portfolio company within HC2’s Pansend Life Sciences (“Pansend”) subsidiary. Pansend is led by David A.…